ArticleMolecular cancer2026
Plasma proteomic and metabolomic profiling reveals molecular features relevant to neoadjuvant therapy response in locally advanced esophageal squamous cell carcinoma.
Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundNeoadjuvant therapy (NAT) followed by radical surgery is the standard treatment for locally advanced esophageal squamous cell carcinoma (LA-ESCC), yet many patients fail to achieve pathologic complete response (pCR). Predictive biomarkers and biological mechanisms underlying NAT resistance remain elusive. We aimed to address this challenge through longitudinal multi-omics profiling of patient plasma during NAT.
methodsWe performed longitudinal plasma proteomic and metabolomic analyses in a discovery cohort of patients with LA-ESCC (n = 40) receiving neoadjuvant chemotherapy (nCT) or neoadjuvant immunochemotherapy (nICT) to reveal molecular features relevant to treatment response. Predictive biomarkers for pCR were assessed in plasma samples from an independent validation cohort (n = 93) by ELISA. Mechanistic studies were conducted through in vitro cell co-culture, in vivo mouse experiments, and analysis of ESCC tissue samples from another validation cohort (n = 33).
resultsMulti-omics analysis revealed distinct molecular profiles between treatment responders and non-responders. Metabolomic profiling revealed dynamic treatment-associated changes in amino acid and lipid metabolism during NAT, and proteomic profiling highlighted baseline differences related to neutrophil activity and inflammatory responses. DEFA1 was validated as an unfavorable predictive biomarker for achieving pCR after nICT. Mechanistic studies demonstrated that DEFA1 fosters an immunosuppressive microenvironment by promoting myeloid-derived suppressor cell (MDSC) differentiation and impairing CD8
conclusionsThis study delineates the longitudinal plasma multi-omic landscape associated with NAT response in LA-ESCC and identifies DEFA1 as a predictive biomarker and potential therapeutic target for overcoming immunotherapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.